Chemed (CHE) Financials

$424.48 -1.34 (-0.32%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$424.31 -0.17 (-0.04%)

As of 05/8/2026 05:40 PM Eastern

Annual Income Statements for Chemed

This table shows Chemed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	110	109	98	206	220	319	269	250	273	302	265
Consolidated Net Income / (Loss)	110	109	98	206	220	319	269	250	273	302	265
Net Income / (Loss) Continuing Operations	110	109	98	206	220	319	269	250	273	302	265
Total Pre-Tax Income	180	177	117	240	262	396	350	330	350	399	356
Total Operating Income	184	179	113	244	257	390	343	343	341	366	338
Total Gross Profit	456	461	516	555	617	701	770	765	799	854	823
Total Revenue	1,543	1,577	1,667	1,783	1,939	2,080	2,139	2,135	2,264	2,431	2,530
Operating Revenue	1,543	1,577	1,667	1,783	1,939	2,080	2,139	2,135	2,264	2,431	2,530
Total Cost of Revenue	1,088	1,115	1,151	1,228	1,321	1,378	1,369	1,370	1,466	1,577	1,707
Operating Cost of Revenue	1,088	1,115	1,151	1,228	1,321	1,378	1,369	1,370	1,466	1,577	1,707
Total Operating Expenses	271	283	403	311	360	312	427	422	458	488	485
Selling, General & Admin Expense	238	248	277	271	306	330	367	359	395	424	417
Depreciation Expense	32	34	35	38	41	47	49	49	51	53	55
Amortization Expense	1.13	0.36	0.14	0.40	4.34	9.99	10	10	10	10	10
Other Operating Expenses / (Income)	-	-	91	1.30	9.13	-75	0.99	3.69	2.26	0.45	2.91
Total Other Income / (Expense), net	-4.33	-1.70	3.88	-4.03	4.23	6.31	7.28	-14	9.80	33	18
Interest Expense	3.65	3.72	4.27	4.99	4.54	2.36	1.87	4.58	3.11	1.78	1.75
Other Income / (Expense), net	-0.69	2.02	8.15	0.96	8.76	8.67	9.14	-9.23	13	35	19
Income Tax Expense	70	68	19	34	42	77	82	80	78	97	91
Basic Earnings per Share	$6.54	$6.64	$6.11	$12.80	$13.77	$20.02	$17.14	$16.72	$18.11	$20.10	$18.42
Weighted Average Basic Shares Outstanding	16.87M	16.38M	16.06M	16.06M	15.97M	15.96M	15.67M	14.93M	15.05M	15.02M	14.40M
Diluted Earnings per Share	$6.33	$6.48	$5.86	$12.23	$13.31	$19.48	$16.85	$16.53	$17.93	$19.89	$18.34
Weighted Average Diluted Shares Outstanding	17.42M	16.79M	16.74M	16.80M	16.53M	16.40M	15.94M	15.10M	15.20M	15.19M	14.46M
Weighted Average Basic & Diluted Shares Outstanding	16.90M	16.40M	83.20M	144.70M	16.06M	16.03M	14.99M	14.95M	15.12M	14.64M	13.77M
Cash Dividends to Common per Share	$0.92	$1.00	$1.08	$1.16	$1.24	$1.32	$1.40	$1.48	$1.56	$1.80	$2.20

This table shows Chemed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	75	90	65	71	76	90	72	52	64	77	66
Consolidated Net Income / (Loss)	75	90	65	71	76	90	72	52	64	77	66
Net Income / (Loss) Continuing Operations	75	90	65	71	76	90	72	52	64	77	66
Total Pre-Tax Income	93	116	84	94	101	120	96	71	84	105	89
Total Operating Income	87	111	72	88	92	114	95	68	75	101	85
Total Gross Profit	202	228	204	206	210	234	216	185	197	225	216
Total Revenue	565	586	589	596	606	640	647	619	625	639	658
Operating Revenue	565	586	589	596	606	640	647	619	625	639	658
Total Cost of Revenue	362	358	385	390	396	406	431	434	428	414	442
Operating Cost of Revenue	362	358	385	390	396	406	431	434	428	414	442
Total Operating Expenses	115	116	132	118	118	120	122	117	122	125	131
Selling, General & Admin Expense	100	100	116	102	102	104	106	100	106	106	114
Depreciation Expense	13	13	13	13	13	13	13	14	14	14	14
Amortization Expense	2.52	2.52	2.52	2.55	2.55	2.57	2.57	2.57	2.57	2.57	2.57
Other Operating Expenses / (Income)	0.34	0.20	0.09	0.04	0.16	0.16	0.05	0.03	0.15	2.68	-0.01
Total Other Income / (Expense), net	6.42	4.20	12	5.70	8.87	6.25	0.92	3.03	8.79	4.79	4.26
Interest Expense	0.44	0.34	0.43	0.43	0.43	0.50	0.33	0.44	0.46	0.52	0.51
Other Income / (Expense), net	6.86	4.54	13	6.13	9.30	6.74	1.25	3.47	9.25	5.31	4.77
Income Tax Expense	18	26	19	23	25	30	24	19	19	29	23
Basic Earnings per Share	$4.97	$5.98	$4.30	$4.70	$5.04	$6.06	$4.91	$3.60	$4.46	$5.45	$4.85
Weighted Average Basic Shares Outstanding	15.08M	15.05M	15.12M	15.10M	15.03M	15.02M	14.62M	14.59M	14.39M	14.40M	13.68M
Diluted Earnings per Share	$4.93	$5.91	$4.24	$4.65	$5.00	$6.00	$4.86	$3.57	$4.46	$5.45	$4.84
Weighted Average Diluted Shares Outstanding	15.20M	15.20M	15.34M	15.25M	15.17M	15.19M	14.76M	14.70M	14.41M	14.46M	13.69M
Weighted Average Basic & Diluted Shares Outstanding	15.06M	15.12M	15.14M	15.05M	14.98M	14.64M	14.63M	14.57M	14.16M	13.77M	13.27M
Cash Dividends to Common per Share	$0.40	-	$0.40	$0.40	$0.50	-	$0.50	$0.50	$0.60	-	$0.60

This table details how cash moves in and out of Chemed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	0.60	0.58	-4.19	-6.29	1.33	157	-130	41	190	-86	-104
Net Cash From Operating Activities	172	135	162	287	301	489	309	310	330	417	388
Net Cash From Continuing Operating Activities	172	135	162	287	301	489	309	310	330	417	388
Net Income / (Loss) Continuing Operations	110	109	98	206	220	319	269	250	273	302	265
Consolidated Net Income / (Loss)	110	109	98	206	220	319	269	250	273	302	265
Depreciation Expense	33	35	36	39	45	57	59	59	61	63	65
Amortization Expense	2.63	2.37	1.75	0.89	0.31	0.31	0.31	0.34	0.58	0.32	0.32
Non-Cash Adjustments To Reconcile Net Income	13	21	38	19	30	31	22	38	41	46	39
Changes in Operating Assets and Liabilities, net	12	-31	-11	23	6.21	82	-41	-37	-45	6.44	19
Net Cash From Investing Activities	-50	-40	-68	-105	-191	-62	-58	-59	-61	-144	-59
Net Cash From Continuing Investing Activities	-50	-40	-68	-105	-191	-62	-58	-59	-61	-144	-59
Purchase of Property, Plant & Equipment	-44	-40	-64	-53	-53	-59	-59	-57	-57	-50	-63
Acquisitions	-6.61	-	-4.73	-53	-138	-3.60	0.00	-3.53	-3.99	-97	-0.23
Sale of Property, Plant & Equipment	-	-	-	-	-	1.69	0.90	2.33	0.64	3.32	4.57
Other Investing Activities, net	0.43	-0.09	1.42	0.82	0.27	-0.82	0.01	-0.88	-0.43	-0.30	-0.89
Net Cash From Financing Activities	-121	-95	-99	-188	-109	-271	-381	-209	-80	-359	-433
Net Cash From Continuing Financing Activities	-121	-95	-99	-188	-109	-271	-381	-209	-80	-359	-433
Repayment of Debt	-161	-110	-220	-484	-482	-265	-25	-311	-98	0.00	0.00
Repurchase of Common Equity	-75	-111	-95	-159	-93	-176	-576	-115	-68	-361	-432
Payment of Dividends	-16	-16	-17	-19	-20	-21	-22	-22	-24	-27	-32
Issuance of Debt	103	127	213	470	483	175	210	221	0.49	-2.02	1.13
Other Financing Activities, net	28	15	20	3.33	1.98	15	33	17	108	31	29

This table details how cash moves in and out of Chemed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	13	91	49	-90	16	-60	-4.47	76	-120	-55	-58
Net Cash From Operating Activities	29	109	85	78	91	165	33	139	83	134	88
Net Cash From Continuing Operating Activities	29	109	85	78	91	165	33	139	83	134	88
Net Income / (Loss) Continuing Operations	75	90	65	71	76	90	72	52	64	77	66
Consolidated Net Income / (Loss)	75	90	65	71	76	90	72	52	64	77	66
Depreciation Expense	15	16	16	16	16	16	16	16	16	16	17
Amortization Expense	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08	0.08
Non-Cash Adjustments To Reconcile Net Income	8.94	10	18	8.00	9.12	11	12	11	7.70	8.90	11
Changes in Operating Assets and Liabilities, net	-70	-7.45	-15	-17	-10	48	-67	59	-4.86	31	-5.67
Net Cash From Investing Activities	-15	-12	-19	-93	-19	-13	-14	-15	-14	-16	-38
Net Cash From Continuing Investing Activities	-15	-12	-19	-93	-19	-13	-14	-15	-14	-16	-38
Purchase of Property, Plant & Equipment	-12	-12	-12	-11	-14	-13	-13	-16	-17	-16	-17
Acquisitions	-3.69	-	-7.30	-85	-5.10	-	-0.23	-	-	-	-21
Sale of Property, Plant & Equipment	0.15	0.13	0.09	2.83	0.14	0.26	0.11	0.37	3.27	0.82	0.13
Other Investing Activities, net	-0.24	-0.03	-0.01	-0.26	-0.02	-0.01	-0.28	-0.04	-0.15	-0.42	-0.20
Net Cash From Financing Activities	-0.26	-6.09	-16	-74	-56	-212	-24	-47	-189	-173	-108
Net Cash From Continuing Financing Activities	-0.26	-6.09	-16	-74	-56	-212	-24	-47	-189	-173	-108
Repayment of Debt	-	-	-	-	-	-2.02	0.16	0.93	-0.18	-0.91	-45
Repurchase of Common Equity	-14	-40	-38	-56	-58	-209	-33	-43	-181	-175	-190
Payment of Dividends	-6.03	-6.06	-6.05	-6.06	-7.49	-7.50	-7.33	-7.22	-8.65	-8.50	-8.17
Issuance of Debt	-0.54	0.53	-0.66	-0.13	0.41	0.39	0.00	-	-	-	135
Other Financing Activities, net	21	39	29	-13	8.45	5.98	17	2.13	0.30	10	-0.66

This table presents Chemed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	852	880	920	976	1,268	1,435	1,343	1,442	1,668	1,669	1,538
Total Current Assets	151	170	176	160	191	329	230	273	501	395	303
Cash & Equivalents	15	15	11	4.83	6.16	163	33	74	264	178	75
Accounts Receivable	106	132	114	120	144	127	137	139	182	171	183
Inventories, net	6.31	5.76	5.33	5.71	7.46	7.10	10	10	12	8.19	7.54
Prepaid Expenses	13	13	16	19	23	26	33	30	30	26	27
Current Deferred & Refundable Income Taxes	11	3.71	30	11	10	6.60	17	19	13	11	11
Plant, Property, & Equipment, net	117	121	143	162	176	188	194	200	204	201	206
Total Noncurrent Assets	584	589	601	654	902	918	919	970	963	1,073	1,030
Noncurrent Note & Lease Receivables	-	-	-	-	112	123	125	136	126	127	131
Goodwill	472	472	477	511	577	579	579	581	585	667	667
Intangible Assets	55	55	55	68	126	118	108	100	90	92	83
Employee Benefit Assets	49	54	62	66	77	89	99	93	106	131	140
Other Noncurrent Operating Assets	7.23	7.04	7.13	9.21	9.05	8.76	8.14	60	56	56	8.65
Total Liabilities & Shareholders' Equity	852	880	920	976	1,268	1,435	1,343	1,442	1,668	1,669	1,538
Total Liabilities	339	356	380	384	542	534	719	643	560	550	559
Total Current Liabilities	171	172	194	192	262	299	302	297	312	286	287
Accounts Payable	44	40	48	50	51	54	73	42	64	44	64
Accrued Expenses	44	48	47	46	50	55	56	59	59	57	62
Current Deferred & Payable Income Tax Liabilities	-	-	-	-	0.13	9.46	0.04	0.00	6.86	7.59	2.50
Current Employee Benefit Liabilities	53	54	63	63	71	91	96	87	88	92	58
Other Current Liabilities	23	22	25	32	90	89	78	104	94	85	100
Total Noncurrent Liabilities	168	184	186	193	279	235	417	346	248	264	272
Long-Term Debt	84	100	91	89	90	0.00	185	93	-	-	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	21	14	17	22	19	21	23	39	30	26	19
Noncurrent Employee Benefit Liabilities	49	54	62	65	76	88	99	92	104	126	136
Other Noncurrent Operating Liabilities	13	16	17	17	95	125	110	123	114	112	116
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	513	524	540	591	727	901	623	799	1,108	1,119	979
Total Preferred & Common Equity	513	524	540	591	727	901	623	799	1,108	1,119	979
Total Common Equity	513	524	540	591	727	901	623	799	1,108	1,119	979
Common Stock	637	674	731	810	896	998	1,081	1,187	1,378	1,522	1,630
Retained Earnings	866	958	1,039	1,226	1,426	1,724	1,970	2,198	2,447	2,722	2,955
Treasury Stock	-992	-1,111	-1,231	-1,446	-1,598	-1,823	-2,430	-2,588	-2,720	-3,127	-3,608
Other Equity Adjustments	2.40	2.51	2.20	2.34	2.31	2.34	2.20	2.25	2.08	2.22	2.36

This table presents Chemed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	1,356	1,431	1,505	1,562	1,728	1,735	1,769	1,727	1,718	1,624	1,536
Total Current Assets	199	262	337	395	540	465	490	502	491	395	274
Cash & Equivalents	7.78	58	160	173	313	223	238	174	250	130	17
Accounts Receivable	122	154	120	168	177	185	196	286	185	216	215
Inventories, net	10	11	12	13	11	11	9.90	7.79	9.15	8.24	7.21
Prepaid Expenses	31	29	29	30	28	29	31	30	33	35	27
Current Deferred & Refundable Income Taxes	28	11	17	11	9.79	17	14	4.44	14	7.11	7.61
Plant, Property, & Equipment, net	194	204	208	205	203	202	201	200	202	204	208
Total Noncurrent Assets	964	965	960	962	985	1,068	1,078	1,024	1,024	1,024	1,054
Noncurrent Note & Lease Receivables	131	131	127	123	132	132	134	131	132	128	134
Goodwill	580	581	582	585	592	662	667	667	667	667	688
Intangible Assets	102	97	95	93	88	97	95	90	87	85	80
Employee Benefit Assets	90	97	100	104	118	121	127	128	130	136	144
Other Noncurrent Operating Assets	60	58	57	57	56	56	56	8.48	8.33	8.14	8.73
Total Liabilities & Shareholders' Equity	1,356	1,431	1,505	1,562	1,728	1,735	1,769	1,727	1,718	1,624	1,536
Total Liabilities	635	551	553	543	544	528	534	545	519	547	688
Total Current Liabilities	298	283	302	297	282	262	265	291	264	292	321
Accounts Payable	77	40	41	57	56	43	45	48	51	48	66
Accrued Expenses	57	63	57	61	62	60	60	66	67	66	65
Current Deferred & Payable Income Tax Liabilities	0.00	11	-	5.14	27	0.00	3.39	38	0.00	1.47	26
Current Employee Benefit Liabilities	67	50	74	75	50	78	73	60	55	80	63
Other Current Liabilities	92	114	130	100	87	80	83	79	91	97	102
Total Noncurrent Liabilities	337	268	251	246	262	266	269	254	255	255	366
Long-Term Debt	96	16	0.00	0.00	-	-	-	-	-	-	91
Noncurrent Deferred & Payable Income Tax Liabilities	34	35	37	30	25	28	28	12	13	9.69	15
Noncurrent Employee Benefit Liabilities	90	97	99	103	118	120	122	127	128	132	143
Other Noncurrent Operating Liabilities	117	119	115	112	120	118	119	115	115	113	118
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	721	880	952	1,019	1,183	1,207	1,236	1,182	1,198	1,077	848
Total Preferred & Common Equity	721	880	952	1,019	1,183	1,207	1,236	1,182	1,198	1,077	848
Total Common Equity	721	880	952	1,019	1,183	1,207	1,236	1,182	1,198	1,077	848
Common Stock	1,137	1,223	1,277	1,291	1,436	1,453	1,500	1,576	1,614	1,619	1,641
Retained Earnings	2,141	2,246	2,294	2,363	2,506	2,571	2,639	2,786	2,832	2,887	3,014
Treasury Stock	-2,559	-2,592	-2,622	-2,637	-2,761	-2,819	-2,905	-3,183	-3,249	-3,431	-3,809
Other Equity Adjustments	2.31	2.28	2.32	2.05	2.12	2.15	2.21	2.26	2.30	2.38	2.40

This table displays calculated financial ratios and metrics derived from Chemed's official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	5.98%	2.17%	5.70%	6.96%	8.75%	7.27%	2.87%	-0.20%	6.06%	7.37%	4.06%
EBITDA Growth	5.60%	-0.96%	-27.19%	79.33%	9.61%	46.07%	-9.60%	-4.32%	5.37%	11.98%	-9.02%
EBIT Growth	7.51%	-1.63%	-32.96%	101.83%	8.81%	49.67%	-11.59%	-5.09%	5.75%	13.51%	-10.90%
NOPAT Growth	9.88%	-2.78%	-13.54%	120.19%	3.52%	45.30%	-16.35%	-1.10%	1.85%	4.60%	-8.99%
Net Income Growth	11.03%	-1.39%	-9.72%	109.36%	7.00%	45.26%	-15.94%	-7.05%	9.17%	10.82%	-12.17%
EPS Growth	13.64%	2.37%	-9.57%	108.70%	8.83%	46.36%	-13.50%	-1.90%	8.47%	10.93%	-7.79%
Operating Cash Flow Growth	55.51%	-21.05%	20.02%	76.71%	4.91%	62.42%	-36.93%	0.42%	6.59%	26.40%	-7.00%
Free Cash Flow Firm Growth	63.23%	-23.97%	0.00%	99.62%	-50.15%	373.29%	-41.47%	-5.64%	13.91%	-25.80%	59.65%
Invested Capital Growth	0.86%	4.71%	2.09%	7.18%	19.94%	-8.87%	4.99%	6.02%	2.66%	11.46%	-3.80%
Revenue Q/Q Growth	1.26%	0.31%	1.52%	1.66%	3.46%	0.53%	0.36%	0.27%	1.76%	2.28%	-0.03%
EBITDA Q/Q Growth	0.11%	1.46%	4.01%	1.99%	7.12%	16.87%	-10.74%	-3.05%	8.60%	1.08%	-3.24%
EBIT Q/Q Growth	-0.30%	1.96%	5.24%	1.97%	6.71%	19.67%	-12.33%	-3.65%	9.93%	1.18%	-3.94%
NOPAT Q/Q Growth	-0.14%	2.43%	26.89%	2.51%	2.65%	17.98%	-11.94%	-5.40%	10.63%	-0.37%	-4.67%
Net Income Q/Q Growth	0.12%	2.12%	29.50%	-0.11%	5.39%	17.76%	-12.72%	-4.77%	11.42%	0.09%	-4.87%
EPS Q/Q Growth	0.48%	3.18%	30.51%	-0.49%	5.80%	18.06%	-11.41%	-3.78%	11.02%	0.45%	-2.91%
Operating Cash Flow Q/Q Growth	-0.50%	-27.51%	-17.94%	42.07%	2.40%	4.99%	-7.02%	13.40%	2.60%	15.60%	-7.48%
Free Cash Flow Firm Q/Q Growth	-3.90%	-31.01%	-25.44%	42.97%	69.43%	4.08%	-4.30%	0.92%	16.95%	42.12%	-8.56%
Invested Capital Q/Q Growth	0.26%	7.11%	16.46%	7.14%	2.16%	7.24%	3.25%	0.93%	-0.26%	-5.68%	-4.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	29.53%	29.26%	30.97%	31.13%	31.85%	33.73%	35.98%	35.84%	35.28%	35.14%	32.54%
EBITDA Margin	14.25%	13.81%	9.51%	15.95%	16.08%	21.89%	19.24%	18.44%	18.32%	19.11%	16.71%
Operating Margin	11.95%	11.34%	6.78%	13.67%	13.28%	18.74%	16.04%	16.09%	15.04%	15.07%	13.37%
EBIT Margin	11.91%	11.46%	7.27%	13.72%	13.73%	19.16%	16.46%	15.66%	15.61%	16.50%	14.13%
Profit (Net Income) Margin	7.14%	6.90%	5.89%	11.53%	11.34%	15.36%	12.55%	11.69%	12.03%	12.42%	10.48%
Tax Burden Percent	61.22%	61.42%	83.97%	85.79%	84.07%	80.68%	76.66%	75.72%	77.78%	75.60%	74.55%
Interest Burden Percent	98.02%	97.94%	96.47%	97.96%	98.30%	99.41%	99.47%	98.63%	99.12%	99.56%	99.51%
Effective Tax Rate	38.78%	38.58%	16.03%	14.21%	15.93%	19.32%	23.34%	24.28%	22.22%	24.40%	25.45%
Return on Invested Capital (ROIC)	19.23%	18.19%	15.21%	32.00%	29.12%	40.59%	34.74%	32.56%	31.80%	31.05%	27.33%
ROIC Less NNEP Spread (ROIC-NNEP)	16.70%	16.96%	18.76%	28.04%	33.34%	27.68%	-70.80%	20.64%	25.46%	19.78%	16.99%
Return on Net Nonoperating Assets (RNNOA)	3.63%	2.78%	3.24%	4.32%	4.26%	-1.34%	0.49%	2.55%	-3.21%	-3.93%	-2.05%
Return on Equity (ROE)	22.86%	20.97%	18.45%	36.33%	33.37%	39.25%	35.23%	35.11%	28.59%	27.12%	25.28%
Cash Return on Invested Capital (CROIC)	18.37%	13.59%	13.15%	25.07%	10.98%	49.88%	29.87%	26.71%	29.18%	20.21%	31.20%
Operating Return on Assets (OROA)	21.47%	20.87%	13.46%	25.81%	23.72%	29.47%	25.36%	24.01%	22.73%	24.05%	22.30%
Return on Assets (ROA)	12.88%	12.55%	10.91%	21.69%	19.60%	23.64%	19.34%	17.93%	17.52%	18.10%	16.54%
Return on Common Equity (ROCE)	22.86%	20.97%	18.45%	36.33%	33.37%	39.25%	35.23%	35.11%	28.59%	27.12%	25.28%
Return on Equity Simple (ROE_SIMPLE)	21.49%	20.75%	18.17%	34.76%	30.27%	35.45%	43.09%	31.25%	24.60%	26.99%	0.00%
Net Operating Profit after Tax (NOPAT)	113	110	95	209	216	314	263	260	265	277	252
NOPAT Margin	7.32%	6.96%	5.69%	11.72%	11.16%	15.12%	12.29%	12.18%	11.70%	11.40%	9.97%
Net Nonoperating Expense Percent (NNEP)	2.53%	1.23%	-3.55%	3.97%	-4.23%	12.91%	105.54%	11.92%	6.34%	11.27%	10.34%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	29.02%	23.91%	24.76%	25.75%
Cost of Revenue to Revenue	70.47%	70.74%	69.03%	68.87%	68.15%	66.27%	64.02%	64.16%	64.72%	64.86%	67.46%
SG&A Expenses to Revenue	15.41%	15.73%	16.60%	15.21%	15.77%	15.88%	17.14%	16.80%	17.45%	17.45%	16.49%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	17.58%	17.93%	24.19%	17.47%	18.57%	14.99%	19.95%	19.75%	20.24%	20.07%	19.17%
Earnings before Interest and Taxes (EBIT)	184	181	121	245	266	398	352	334	353	401	358
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	220	218	159	284	312	455	412	394	415	465	423
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.76	4.83	7.02	7.53	9.54	9.32	12.95	9.44	7.92	7.09	6.18
Price to Tangible Book Value (P/TBV)	0.00	0.00	441.28	356.06	302.97	41.04	0.00	64.04	20.28	22.03	26.36
Price to Revenue (P/Rev)	1.58	1.61	2.28	2.50	3.57	4.04	3.77	3.53	3.87	3.26	2.39
Price to Earnings (P/E)	22.14	23.29	38.66	21.67	31.51	26.28	30.06	30.19	32.19	26.26	22.82
Dividend Yield	0.64%	0.64%	0.45%	0.42%	0.29%	0.25%	0.27%	0.37%	0.27%	0.34%	0.51%
Earnings Yield	4.52%	4.29%	2.59%	4.61%	3.17%	3.81%	3.33%	3.31%	3.11%	3.81%	4.38%
Enterprise Value to Invested Capital (EV/IC)	4.27	4.25	6.16	6.72	8.65	11.15	10.61	9.20	10.08	8.24	6.61
Enterprise Value to Revenue (EV/Rev)	1.63	1.67	2.33	2.55	3.62	3.96	3.84	3.54	3.76	3.19	2.36
Enterprise Value to EBITDA (EV/EBITDA)	11.45	12.06	24.51	15.96	22.50	18.08	19.98	19.20	20.50	16.69	14.14
Enterprise Value to EBIT (EV/EBIT)	13.70	14.53	32.07	18.56	26.35	20.67	23.35	22.62	24.07	19.32	16.72
Enterprise Value to NOPAT (EV/NOPAT)	22.30	23.92	40.94	21.72	32.41	26.19	31.27	29.07	32.12	27.98	23.71
Enterprise Value to Operating Cash Flow (EV/OCF)	14.69	19.39	23.91	15.81	23.28	16.82	26.65	24.40	25.76	18.57	15.40
Enterprise Value to Free Cash Flow (EV/FCFF)	23.35	32.01	47.38	27.72	85.92	21.31	36.37	35.43	35.00	42.98	20.76
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.18	0.21	0.19	0.15	0.12	0.00	0.30	0.12	0.00	0.00	0.00
Long-Term Debt to Equity	0.16	0.19	0.17	0.15	0.12	0.00	0.30	0.12	0.00	0.00	0.00
Financial Leverage	0.22	0.16	0.17	0.15	0.13	-0.05	-0.01	0.12	-0.13	-0.20	-0.12
Leverage Ratio	1.78	1.67	1.69	1.68	1.70	1.66	1.82	1.96	1.63	1.50	1.53
Compound Leverage Factor	1.74	1.64	1.63	1.64	1.67	1.65	1.81	1.93	1.62	1.49	1.52
Debt to Total Capital	15.10%	17.18%	15.77%	13.11%	11.02%	0.00%	22.89%	10.88%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	1.24%	1.38%	1.56%	0.00%	0.00%	0.00%	0.00%	0.56%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	13.85%	15.80%	14.22%	13.11%	11.02%	0.00%	22.89%	10.32%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.91%	82.82%	84.23%	86.89%	88.98%	100.00%	77.11%	89.12%	100.00%	100.00%	100.00%
Debt to EBITDA	0.42	0.50	0.64	0.31	0.29	0.00	0.45	0.25	0.00	0.00	0.00
Net Debt to EBITDA	0.35	0.43	0.57	0.30	0.27	0.00	0.37	0.06	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.38	0.46	0.58	0.31	0.29	0.00	0.45	0.23	0.00	0.00	0.00
Debt to NOPAT	0.81	0.99	1.07	0.43	0.42	0.00	0.70	0.37	0.00	0.00	0.00
Net Debt to NOPAT	0.68	0.85	0.95	0.40	0.39	0.00	0.58	0.09	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.74	0.91	0.96	0.43	0.42	0.00	0.70	0.36	0.00	0.00	0.00
Altman Z-Score	8.24	8.26	9.80	11.33	11.40	13.51	11.18	11.39	13.64	13.27	11.61
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.88	0.99	0.91	0.83	0.73	1.10	0.76	0.92	1.61	1.38	1.05
Quick Ratio	0.71	0.86	0.64	0.65	0.57	0.97	0.56	0.72	1.43	1.22	0.90
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	108	82	82	164	82	386	226	213	243	180	288
Operating Cash Flow to CapEx	388.58%	340.42%	252.71%	543.08%	568.16%	856.33%	534.17%	563.48%	587.57%	903.36%	666.82%
Free Cash Flow to Firm to Interest Expense	29.60	22.08	19.20	32.81	18.00	164.03	121.05	46.55	78.20	101.32	164.53
Operating Cash Flow to Interest Expense	47.05	36.45	38.04	57.54	66.43	207.77	165.20	67.60	106.27	234.55	221.87
Operating Cash Flow Less CapEx to Interest Expense	34.94	25.74	22.99	46.95	54.74	183.50	134.28	55.60	88.19	208.58	188.60
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.80	1.82	1.85	1.88	1.73	1.54	1.54	1.53	1.46	1.46	1.58
Accounts Receivable Turnover	13.37	13.24	13.57	15.29	14.72	15.37	16.20	15.44	14.11	13.79	14.30
Inventory Turnover	174.27	184.84	207.51	222.42	200.67	189.35	159.20	134.43	131.59	156.16	216.93
Fixed Asset Turnover	13.86	13.21	12.61	11.69	11.48	11.44	11.22	10.85	11.22	12.02	12.45
Accounts Payable Turnover	24.02	26.79	26.16	24.92	26.10	26.17	21.52	23.84	27.67	29.15	31.43
Days Sales Outstanding (DSO)	27.30	27.58	26.90	23.87	24.79	23.75	22.53	23.65	25.86	26.47	25.52
Days Inventory Outstanding (DIO)	2.09	1.97	1.76	1.64	1.82	1.93	2.29	2.72	2.77	2.34	1.68
Days Payable Outstanding (DPO)	15.19	13.63	13.95	14.65	13.99	13.95	16.96	15.31	13.19	12.52	11.61
Cash Conversion Cycle (CCC)	14.20	15.93	14.71	10.86	12.62	11.73	7.86	11.05	15.45	16.29	15.59
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	590	618	630	676	810	739	775	822	844	941	905
Invested Capital Turnover	2.63	2.61	2.67	2.73	2.61	2.69	2.83	2.67	2.72	2.72	2.74
Increase / (Decrease) in Invested Capital	5.05	28	13	45	135	-72	37	47	22	97	-36
Enterprise Value (EV)	2,518	2,626	3,886	4,539	7,013	8,232	8,223	7,561	8,508	7,752	5,978
Market Capitalization	2,442	2,532	3,796	4,455	6,929	8,395	8,071	7,537	8,772	7,931	6,053
Book Value per Share	$30.41	$32.30	$33.84	$36.93	$45.39	$56.50	$40.49	$53.71	$73.55	$74.69	$69.15
Tangible Book Value per Share	($0.84)	($0.21)	$0.54	$0.78	$1.43	$12.82	($4.12)	$7.91	$28.72	$24.03	$16.21
Total Capital	605	633	642	681	817	901	808	896	1,108	1,119	979
Total Debt	91	109	101	89	90	0.00	185	98	0.00	0.00	0.00
Total Long-Term Debt	84	100	91	89	90	0.00	185	93	0.00	0.00	0.00
Net Debt	77	93	90	84	84	-163	152	23	-264	-178	-75
Capital Expenditures (CapEx)	44	40	64	53	53	57	58	55	56	46	58
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-28	-8.49	-19	-37	-78	-132	-105	-94	-75	-69	-59
Debt-free Net Working Capital (DFNWC)	-13	6.82	-7.48	-32	-72	30	-72	-20	189	109	15
Net Working Capital (NWC)	-21	-1.93	-17	-32	-72	30	-72	-25	189	109	15
Net Nonoperating Expense (NNE)	2.65	1.04	-3.26	3.46	-3.56	-5.09	-5.58	10	-7.62	-25	-13
Net Nonoperating Obligations (NNO)	77	93	90	84	84	-163	152	23	-264	-178	-75
Total Depreciation and Amortization (D&A)	36	37	37	40	46	57	59	60	61	63	65
Debt-free, Cash-free Net Working Capital to Revenue	-1.80%	-0.54%	-1.12%	-2.06%	-4.01%	-6.37%	-4.91%	-4.39%	-3.32%	-2.85%	-2.33%
Debt-free Net Working Capital to Revenue	-0.84%	0.43%	-0.45%	-1.79%	-3.69%	1.46%	-3.37%	-0.92%	8.34%	4.49%	0.61%
Net Working Capital to Revenue	-1.33%	-0.12%	-1.05%	-1.79%	-3.69%	1.46%	-3.37%	-1.15%	8.34%	4.49%	0.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$6.54	$6.64	$6.11	$12.80	$13.77	$20.02	$17.14	$16.72	$18.11	$20.10	$18.42
Adjusted Weighted Average Basic Shares Outstanding	16.87M	16.38M	16.06M	16.06M	15.97M	15.96M	15.67M	14.93M	15.05M	15.02M	14.40M
Adjusted Diluted Earnings per Share	$6.33	$6.48	$5.86	$12.23	$13.31	$19.48	$16.85	$16.53	$17.93	$19.89	$18.34
Adjusted Weighted Average Diluted Shares Outstanding	17.42M	16.79M	16.74M	16.80M	16.53M	16.40M	15.94M	15.10M	15.20M	15.19M	14.46M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	16.99M	16.31M	16.16M	15.97M	16.06M	16.03M	14.99M	14.95M	15.12M	14.64M	13.77M
Normalized Net Operating Profit after Tax (NOPAT)	113	110	95	209	216	314	263	260	265	277	252
Normalized NOPAT Margin	7.32%	6.96%	5.69%	11.72%	11.16%	15.12%	12.29%	12.18%	11.70%	11.40%	9.97%
Pre Tax Income Margin	11.67%	11.23%	7.01%	13.44%	13.50%	19.04%	16.38%	15.44%	15.47%	16.43%	14.06%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	50.42	48.66	28.37	49.02	58.69	169.15	188.53	72.92	113.73	225.42	204.30
NOPAT to Interest Expense	30.98	29.55	22.22	41.88	47.71	133.49	140.78	56.74	85.23	155.66	144.10
EBIT Less CapEx to Interest Expense	38.31	37.95	13.32	38.42	46.99	144.89	157.61	60.92	95.64	199.45	171.03
NOPAT Less CapEx to Interest Expense	18.87	18.85	7.17	31.29	36.02	109.23	109.85	44.74	67.14	129.69	110.82
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	14.15%	15.12%	17.69%	9.08%	9.00%	6.60%	8.20%	8.82%	8.62%	8.97%	11.95%
Augmented Payout Ratio	82.22%	117.27%	114.09%	86.38%	51.12%	61.56%	222.70%	54.70%	33.47%	128.64%	174.63%

This table displays calculated financial ratios and metrics derived from Chemed's official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	13,274,104.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	13,274,104.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	4.99
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.23%	7.18%	5.19%	7.60%	7.38%	9.23%	9.79%	3.85%	3.09%	-0.10%	1.63%
EBITDA Growth	18.01%	33.28%	15.05%	27.10%	7.39%	3.78%	11.21%	-20.13%	-14.43%	-10.37%	-5.17%
EBIT Growth	20.54%	38.02%	16.77%	32.54%	8.27%	4.04%	13.06%	-24.08%	-17.20%	-12.15%	-6.93%
NOPAT Growth	16.08%	41.53%	0.52%	26.24%	-0.98%	-1.33%	27.67%	-24.52%	-16.85%	-14.44%	-11.18%
Net Income Growth	31.80%	44.95%	20.13%	32.80%	1.09%	0.30%	10.37%	-25.95%	-15.23%	-15.02%	-7.60%
EPS Growth	30.42%	43.10%	18.44%	32.48%	1.42%	1.52%	14.62%	-23.23%	-10.80%	-9.17%	-0.41%
Operating Cash Flow Growth	-44.39%	8.35%	39.77%	-41.42%	212.92%	51.91%	-61.27%	78.81%	-7.88%	-19.03%	169.42%
Free Cash Flow Firm Growth	1,232.00%	344.70%	248.87%	-338.42%	-314.93%	-117.09%	-331.72%	168.49%	231.38%	1,082.00%	323.00%
Invested Capital Growth	3.88%	2.66%	3.19%	24.27%	17.87%	11.46%	15.83%	-3.64%	-5.05%	-3.80%	-8.49%
Revenue Q/Q Growth	1.93%	3.79%	0.57%	1.13%	1.73%	5.58%	1.09%	-4.35%	0.99%	2.31%	2.84%
EBITDA Q/Q Growth	26.08%	20.51%	-23.38%	9.18%	6.53%	16.46%	-17.90%	-21.59%	14.13%	21.99%	-13.13%
EBIT Q/Q Growth	31.77%	23.72%	-26.76%	11.01%	7.64%	18.89%	-20.41%	-25.46%	17.39%	26.15%	-15.68%
NOPAT Q/Q Growth	32.35%	24.33%	-35.86%	19.61%	3.82%	23.87%	-17.00%	-29.29%	14.37%	27.47%	-13.84%
Net Income Q/Q Growth	40.43%	20.14%	-27.80%	9.03%	6.90%	19.19%	-20.55%	-26.85%	22.37%	19.48%	-13.61%
EPS Q/Q Growth	40.46%	19.88%	-28.26%	9.67%	7.53%	20.00%	-19.00%	-26.54%	24.93%	22.20%	-11.19%
Operating Cash Flow Q/Q Growth	-78.14%	275.30%	-22.12%	-8.32%	16.77%	82.19%	-80.14%	323.30%	-39.84%	60.13%	-33.93%
Free Cash Flow Firm Q/Q Growth	-27.53%	70.06%	-55.71%	-536.79%	34.67%	86.48%	-500.50%	229.11%	25.30%	1.08%	36.37%
Invested Capital Q/Q Growth	6.81%	-0.26%	3.11%	13.13%	1.31%	-5.68%	7.15%	-5.88%	-0.17%	-4.44%	1.93%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	35.81%	38.84%	34.64%	34.59%	34.64%	36.58%	33.45%	29.85%	31.51%	35.22%	32.82%
EBITDA Margin	19.34%	22.45%	17.11%	18.47%	19.34%	21.33%	17.33%	14.20%	16.05%	19.14%	16.17%
Operating Margin	15.38%	19.01%	12.28%	14.79%	15.20%	17.79%	14.65%	11.00%	11.96%	15.74%	12.86%
EBIT Margin	16.60%	19.79%	14.41%	15.82%	16.74%	18.85%	14.84%	11.56%	13.44%	16.57%	13.59%
Profit (Net Income) Margin	13.28%	15.37%	11.03%	11.90%	12.50%	14.11%	11.09%	8.48%	10.28%	12.00%	10.08%
Tax Burden Percent	80.37%	77.91%	76.96%	75.55%	75.00%	75.19%	75.00%	73.81%	76.89%	72.79%	74.63%
Interest Burden Percent	99.53%	99.71%	99.50%	99.54%	99.58%	99.59%	99.66%	99.38%	99.46%	99.51%	99.43%
Effective Tax Rate	19.63%	22.09%	23.04%	24.45%	25.00%	24.81%	25.00%	26.19%	23.11%	27.21%	25.37%
Return on Invested Capital (ROIC)	33.14%	40.26%	25.29%	29.38%	29.41%	36.45%	29.12%	21.11%	23.94%	31.42%	25.27%
ROIC Less NNEP Spread (ROIC-NNEP)	20.26%	37.54%	19.95%	27.13%	26.18%	34.33%	28.84%	20.16%	20.27%	28.66%	18.88%
Return on Net Nonoperating Assets (RNNOA)	-0.93%	-4.74%	-3.39%	-4.81%	-4.78%	-6.82%	-5.94%	-3.96%	-3.23%	-3.45%	-0.93%
Return on Equity (ROE)	32.20%	35.53%	21.91%	24.57%	24.63%	29.64%	23.18%	17.15%	20.72%	27.96%	24.35%
Cash Return on Invested Capital (CROIC)	25.03%	29.18%	27.79%	9.74%	13.77%	20.21%	16.47%	32.27%	32.39%	31.20%	34.17%
Operating Return on Assets (OROA)	25.31%	28.81%	20.93%	22.80%	23.89%	27.47%	21.39%	16.83%	20.05%	26.15%	21.17%
Return on Assets (ROA)	20.25%	22.38%	16.02%	17.15%	17.84%	20.57%	15.99%	12.34%	15.33%	18.94%	15.71%
Return on Common Equity (ROCE)	32.20%	35.53%	21.91%	24.57%	24.63%	29.64%	23.18%	17.15%	20.72%	27.96%	24.35%
Return on Equity Simple (ROE_SIMPLE)	24.00%	0.00%	23.95%	24.92%	24.42%	0.00%	26.13%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	70	87	56	67	69	86	71	50	57	73	63
NOPAT Margin	12.36%	14.81%	9.45%	11.17%	11.40%	13.38%	10.99%	8.12%	9.20%	11.46%	9.60%
Net Nonoperating Expense Percent (NNEP)	12.88%	2.72%	5.34%	2.25%	3.23%	2.12%	0.28%	0.95%	3.67%	2.76%	6.39%
Return On Investment Capital (ROIC_SIMPLE)	-	7.83%	-	-	-	7.65%	6.01%	4.19%	5.34%	7.48%	6.72%
Cost of Revenue to Revenue	64.19%	61.16%	65.36%	65.41%	65.36%	63.42%	66.55%	70.15%	68.49%	64.78%	67.18%
SG&A Expenses to Revenue	17.64%	17.14%	19.67%	17.16%	16.82%	16.29%	16.32%	16.21%	16.93%	16.50%	17.39%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	20.43%	19.83%	22.36%	19.80%	19.44%	18.79%	18.80%	18.84%	19.55%	19.48%	19.95%
Earnings before Interest and Taxes (EBIT)	94	116	85	94	101	121	96	72	84	106	89
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	109	132	101	110	117	137	112	88	100	122	106
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.66	7.92	8.19	6.80	7.32	7.09	7.62	5.94	6.06	6.18	6.13
Price to Tangible Book Value (P/TBV)	22.88	20.28	19.23	18.31	19.08	22.03	21.20	16.04	20.09	26.36	64.93
Price to Revenue (P/Rev)	3.51	3.87	4.22	3.51	3.80	3.26	3.62	2.84	2.58	2.39	2.05
Price to Earnings (P/E)	31.94	32.19	34.19	27.27	29.98	26.26	29.17	24.53	23.40	22.82	20.02
Dividend Yield	0.37%	0.27%	0.25%	0.30%	0.28%	0.34%	0.31%	0.41%	0.47%	0.51%	0.61%
Earnings Yield	3.13%	3.11%	2.93%	3.67%	3.34%	3.81%	3.43%	4.08%	4.27%	4.38%	5.00%
Enterprise Value to Invested Capital (EV/IC)	9.03	10.08	10.77	8.11	8.83	8.24	8.76	7.25	6.75	6.61	5.72
Enterprise Value to Revenue (EV/Rev)	3.43	3.76	4.09	3.42	3.70	3.19	3.55	2.74	2.53	2.36	2.08
Enterprise Value to EBITDA (EV/EBITDA)	19.99	20.50	21.90	17.68	19.16	16.69	18.56	15.15	14.64	14.14	12.65
Enterprise Value to EBIT (EV/EBIT)	23.76	24.07	25.64	20.54	22.21	19.32	21.42	17.64	17.18	16.72	15.03
Enterprise Value to NOPAT (EV/NOPAT)	31.90	32.12	35.38	28.64	31.67	27.98	30.21	24.90	24.17	23.71	21.59
Enterprise Value to Operating Cash Flow (EV/OCF)	23.73	25.76	26.46	26.65	24.38	18.57	24.15	16.11	15.24	15.40	11.89
Enterprise Value to Free Cash Flow (EV/FCFF)	36.76	35.00	39.37	92.25	69.40	42.98	57.11	22.04	20.31	20.76	15.99
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.11
Financial Leverage	-0.05	-0.13	-0.17	-0.18	-0.18	-0.20	-0.21	-0.20	-0.16	-0.12	-0.05
Leverage Ratio	1.68	1.63	1.53	1.50	1.48	1.50	1.46	1.44	1.47	1.53	1.61
Compound Leverage Factor	1.67	1.63	1.52	1.49	1.47	1.49	1.46	1.43	1.46	1.52	1.60
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.71%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	9.71%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	90.29%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.18
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.22
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.30
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.37
Altman Z-Score	12.45	13.17	14.38	13.07	13.94	12.72	13.95	12.30	11.45	11.07	9.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.33	1.61	1.91	1.78	1.85	1.38	1.73	1.86	1.35	1.05	0.85
Quick Ratio	1.15	1.43	1.74	1.56	1.64	1.22	1.58	1.65	1.18	0.90	0.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	38	65	29	-126	-82	-11	-67	86	108	109	149
Operating Cash Flow to CapEx	251.34%	932.27%	700.08%	941.65%	675.46%	1,318.67%	248.66%	897.71%	591.92%	859.78%	519.49%
Free Cash Flow to Firm to Interest Expense	86.02	189.92	67.69	-292.92	-192.25	-22.25	-202.63	194.29	235.99	209.25	290.36
Operating Cash Flow to Interest Expense	65.15	317.44	198.94	180.69	211.99	330.49	99.53	312.88	182.47	256.30	172.30
Operating Cash Flow Less CapEx to Interest Expense	39.23	283.39	170.52	161.50	180.60	305.42	59.50	278.03	151.64	226.49	139.13
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	1.53	1.46	1.45	1.44	1.43	1.46	1.44	1.46	1.49	1.58	1.56
Accounts Receivable Turnover	15.36	14.11	13.85	15.30	13.04	13.79	10.75	13.58	12.28	14.30	10.13
Inventory Turnover	126.79	131.59	138.48	133.42	136.49	156.16	175.37	167.65	187.30	216.93	229.10
Fixed Asset Turnover	11.15	11.22	11.27	11.38	11.70	12.02	12.37	12.42	12.50	12.45	12.47
Accounts Payable Turnover	21.80	27.67	30.68	35.58	30.15	29.15	31.23	35.51	36.51	31.43	30.30
Days Sales Outstanding (DSO)	23.76	25.86	26.35	23.85	27.98	26.47	33.96	26.87	29.72	25.52	36.01
Days Inventory Outstanding (DIO)	2.88	2.77	2.64	2.74	2.67	2.34	2.08	2.18	1.95	1.68	1.59
Days Payable Outstanding (DPO)	16.75	13.19	11.90	10.26	12.11	12.52	11.69	10.28	10.00	11.61	12.05
Cash Conversion Cycle (CCC)	9.89	15.45	17.09	16.33	18.55	16.29	24.36	18.77	21.67	15.59	25.56
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	846	844	870	984	997	941	1,008	949	947	905	922
Invested Capital Turnover	2.68	2.72	2.68	2.63	2.58	2.72	2.65	2.60	2.60	2.74	2.63
Increase / (Decrease) in Invested Capital	32	22	27	192	151	97	138	-36	-50	-36	-86
Enterprise Value (EV)	7,639	8,508	9,375	7,984	8,806	7,752	8,832	6,874	6,395	5,978	5,274
Market Capitalization	7,812	8,772	9,689	8,207	9,045	7,931	9,006	7,124	6,524	6,053	5,200
Book Value per Share	$67.60	$73.55	$78.29	$79.75	$82.11	$74.69	$80.74	$81.92	$73.89	$69.15	$61.60
Tangible Book Value per Share	$22.65	$28.72	$33.33	$29.60	$31.50	$24.03	$29.03	$30.36	$22.29	$16.21	$5.82
Total Capital	1,019	1,108	1,183	1,207	1,236	1,119	1,182	1,198	1,077	979	939
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	91
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	91
Net Debt	-173	-264	-313	-223	-238	-178	-174	-250	-130	-75	74
Capital Expenditures (CapEx)	12	12	12	8.23	13	13	13	15	14	16	17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-76	-75	-56	-20	-13	-69	38	-22	-27	-59	-64
Debt-free Net Working Capital (DFNWC)	97	189	258	203	226	109	212	227	103	15	-47
Net Working Capital (NWC)	97	189	258	203	226	109	212	227	103	15	-47
Net Nonoperating Expense (NNE)	-5.16	-3.27	-9.35	-4.31	-6.65	-4.70	-0.69	-2.24	-6.76	-3.49	-3.18
Net Nonoperating Obligations (NNO)	-173	-264	-313	-223	-238	-178	-174	-250	-130	-75	74
Total Depreciation and Amortization (D&A)	15	16	16	16	16	16	16	16	16	16	17
Debt-free, Cash-free Net Working Capital to Revenue	-3.41%	-3.32%	-2.43%	-0.86%	-0.54%	-2.85%	1.52%	-0.89%	-1.05%	-2.33%	-2.53%
Debt-free Net Working Capital to Revenue	4.37%	8.34%	11.23%	8.69%	9.49%	4.49%	8.51%	9.06%	4.08%	0.61%	-1.86%
Net Working Capital to Revenue	4.37%	8.34%	11.23%	8.69%	9.49%	4.49%	8.51%	9.06%	4.08%	0.61%	-1.86%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$4.97	$5.98	$4.30	$4.70	$5.04	$6.06	$4.91	$3.60	$4.46	$5.45	$4.85
Adjusted Weighted Average Basic Shares Outstanding	15.08M	15.05M	15.12M	15.10M	15.03M	15.02M	14.62M	14.59M	14.39M	14.40M	13.68M
Adjusted Diluted Earnings per Share	$4.93	$5.91	$4.24	$4.65	$5.00	$6.00	$4.86	$3.57	$4.46	$5.45	$4.84
Adjusted Weighted Average Diluted Shares Outstanding	15.20M	15.20M	15.34M	15.25M	15.17M	15.19M	14.76M	14.70M	14.41M	14.46M	13.69M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	15.06M	15.12M	15.14M	15.05M	14.98M	14.64M	14.63M	14.57M	14.16M	13.77M	13.27M
Normalized Net Operating Profit after Tax (NOPAT)	70	87	56	67	69	86	71	50	57	73	63
Normalized NOPAT Margin	12.36%	14.81%	9.45%	11.17%	11.40%	13.38%	10.99%	8.12%	9.20%	11.46%	9.60%
Pre Tax Income Margin	16.52%	19.73%	14.34%	15.75%	16.67%	18.77%	14.79%	11.49%	13.37%	16.49%	13.51%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	211.06	338.99	199.79	219.71	237.60	241.73	291.80	161.53	183.81	203.39	174.52
NOPAT to Interest Expense	157.21	253.75	130.98	155.19	161.88	171.59	216.02	113.44	125.77	140.62	123.28
EBIT Less CapEx to Interest Expense	185.14	304.94	171.37	200.52	206.22	216.67	251.78	126.68	152.98	173.58	141.35
NOPAT Less CapEx to Interest Expense	131.29	219.70	102.56	136.01	130.49	146.53	175.99	78.59	94.94	110.81	90.12
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	9.43%	8.62%	8.42%	8.04%	8.50%	8.97%	9.19%	10.17%	11.01%	11.95%	12.53%
Augmented Payout Ratio	26.09%	33.47%	45.88%	57.39%	72.13%	128.64%	124.54%	128.42%	178.25%	174.63%	238.99%

Financials Breakdown Chart

Key Financial Trends

CHEMED Corp. has shown a generally solid earnings and cash-flow profile over the last four years, marked by steady revenue growth into 2024, a meaningful rise in net income and EPS, and sizable stock repurchases that boosted per-share results. In 2025, top-line growth remained modest and earnings pressures appeared, even as the company continued aggressive capital return. Overall, CHEMED remains financially robust, but near-term momentum has cooled from the 2023–2024 highs.

Four-year revenue trend: operating revenue rose from about $546.7 million in 2022 Q4 to about $640.0 million in 2024 Q4, roughly +17%, with 2025 Q4 essentially flat at about $639.3 million.
Profitability improvement: net income rose from about $62.1 million in 2022 Q4 to about $90.1 million in 2024 Q4, with diluted EPS reaching around $6.06 in 2024 Q4, signaling stronger margins alongside the revenue growth.
Healthy operating cash flow: net cash from continuing operating activities grew from about $100.2 million in 2022 Q4 to about $164.9 million in 2024 Q4, indicating robust cash generation relative to earnings.
Aggressive capital return: CHEMED executed substantial stock repurchases in 2024–2025 (e.g., around $209.3 million in 2024 Q4, ~$180.8 million in 2025 Q3, and ~\$174.6 million in 2025 Q4), helping lift per-share metrics even as growth slowed.
Revenue stability in 2025: CHEMED’s 2025 Q4 revenue sits around $639.3 million, essentially flat vs. 2024, suggesting limited top-line acceleration in the latest year.
Earnings moderation in 2025: net income declined in 2025 relative to 2024 (Q4 2025 net income roughly $76.8 million vs. $90.1 million in 2024 Q4), indicating earnings pressure despite buybacks.
Liquidity signal remains strong, but cash flow cadence showed variability: 2025 quarters displayed some negative net cash from financing activities, contributing to occasional cash-balance pressure despite solid overall cash generation.
Balance-sheet mix shifted: total assets declined from about $1.77 billion in 2024 to about $1.62 billion in 2025, a change that aligns with large equity outlays and ongoing reallocation of resources.
Earnings downbeat versus 2024: the drop in net income in 2025 compared to 2024 could temper the forward-looking earnings growth narrative, especially if buybacks don’t translate into improved cash returns.
Pressure on cash balance due to large buybacks: continued heavy repurchases in 2024–2025 have a material cash-out impact, potentially limiting liquidity for acquisitions or other strategic uses if operating cash flow slows.

05/09/26 10:52 PM ETAI Generated. May Contain Errors.

Chemed Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Chemed's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Chemed's net income appears to be on an upward trend, with a most recent value of $265.24 million in 2025, rising from $110.27 million in 2015. The previous period was $302.00 million in 2024. Check out Chemed's forecast to explore projected trends and price targets.

Chemed's total operating income in 2025 was $338.25 million, based on the following breakdown:

Total Gross Profit: $823.18 million
Total Operating Expenses: $484.94 million

Over the last 10 years, Chemed's total revenue changed from $1.54 billion in 2015 to $2.53 billion in 2025, a change of 63.9%.

Chemed's total liabilities were at $558.78 million at the end of 2025, a 1.7% increase from 2024, and a 64.8% increase since 2015.

In the past 10 years, Chemed's cash and equivalents has ranged from $4.83 million in 2018 to $263.96 million in 2023, and is currently $74.52 million as of their latest financial filing in 2025.

Over the last 10 years, Chemed's book value per share changed from 30.41 in 2015 to 69.15 in 2025, a change of 127.4%.

Related Companies

Financial statements for NYSE:CHE last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemed (CHE) Financials

Financials Breakdown Chart

Key Financial Trends

Chemed Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemed (CHE) Financials

Annual Income Statements for Chemed

Quarterly Income Statements for Chemed

Annual Cash Flow Statements for Chemed

Quarterly Cash Flow Statements for Chemed

Annual Balance Sheets for Chemed

Quarterly Balance Sheets for Chemed

Annual Metrics And Ratios for Chemed

Quarterly Metrics And Ratios for Chemed

Financials Breakdown Chart

Key Financial Trends

Chemed Financials - Frequently Asked Questions

When does Chemed's financial year end?

How has Chemed's net income changed over the last 10 years?

What is Chemed's operating income?

How has Chemed's revenue changed over the last 10 years?

How much debt does Chemed have?

How much cash does Chemed have?

How has Chemed's book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools